CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine

Pharmacogenetics and Genomics

Volumn 17, Issue 11, 2007, Pages 989-993

  Aklillu, Eleni ^a   Kalow, Werner ^b   Endrenyi, Laszlo ^b   Harper, Patricia ^b   Miura, Jun ^a   Ozdemir, Vural ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

5 methoxytryptamine; Antipsychotics; CYP2D6; DRD2; Hyperprolactinemia; Perphenazine; Pharmacodynamic sensitivity; Pituitary; Polymorphism; Prolactin response

Indexed keywords

CYSTEINE; CYTOCHROME P450 2D6; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; PERPHENAZINE; PLACEBO; PROLACTIN; SERINE;

ALLELE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYP2D6 GENE; DOUBLE BLIND PROCEDURE; DRD2 GENE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; GENE; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NEUROIMAGING; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE DRUG DOSE;

ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CYTOCHROME P-450 CYP2D6; DOUBLE-BLIND METHOD; GENOTYPE; HUMANS; PERPHENAZINE; PITUITARY GLAND; POLYMORPHISM, GENETIC; PROLACTIN; RECEPTORS, DOPAMINE D2; TAQ POLYMERASE; TIME FACTORS;

EID: 37349117305     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3282f01aa3     Document Type: Article

References (30)

1. Simpson GM. Atypical antipsychotics and the burden of disease. Am J Manag Care 2005; 11 (Suppl 8):S235-S241.
2. Lin KM, Poland RE, Lau JK, Rubin RT. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 1988; 8:195-201.
3. Ozdemir V, Aklillu E, Mee S, Bertilsson L, Albers LJ, Graham JE, et al. Pharmacogenetics for off-patent antipsychotics: re-defining the risk for tardive dyskinesia and access to essential medicines. Expert Opin Pharmacother 2006; 7:119-133.
4. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223.
5. Gunes A, Scordo MG, Jaanson P, Dahl ML. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. Psychopharmacology (Berl) 2007; 190:479-484.
6. Mihara K, Suzuki A, Kondo T, Yasui-Furukori N, Ono S, Otani K, et al. Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. Am J Med Genet Part B 2001; 105:271-274.
7. Bondy B, Zill P. Pharmacogenetics and psychopharmacology. Curr Opin Pharmacol 2004; 4:72-78.
8. Kirchheiner J, Fuhr U, Brockmoller J. Pharmacogenetics-based therapeutic recommendations - ready for clinical practice? Nat Rev Drug Discov 2005; 4:639-647.
9. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007; Advance online publication - DOI: 10.1038/sj.mp.4002009.
10. Mihara K, Kondo T, Suzuki A, Yasui N, Nagashima U, Ono S, et al. Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene. Psychopharmacology (Berl) 2000; 149:246-250.
11. Young RM, Lawford BR, Barnes M, Burton SC, Ritchie T, Ward WK, et al. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry 2004; 185:147-151.
12. Grandy DK, Litt M, Allen L, Bunzow JR, Marchionni M, Makam H, et al. The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. Am J Hum Genet 1989; 45:778-785.
13. Gelernter J, Kranzler H, Cubells JF, Ichinose H, Nagatsu T. DRD2 allele frequencies and linkage disequilibria, including the -141CIns/Del promoter polymorphism, in European-American, African-American, and Japanese subjects. Genomics 1998; 51:21-26.
14. Ritchie T, Noble EP. Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 2003; 28:73-82.
15. Pohjalainen T, Rinne JO, Nagren K, Lehikoinen P, Anttila K, Syvalahti EK, Hietala J. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998; 3:256-260.
16. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK, et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997; 7:479-484.
17. Hauge XY, Grandy DK, Eubanks JH, Evans GA, Civelli O, Litt M. Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene. Genomics 1991; 10:527-530.
18. Oliveri RL, Annesi G, Zappia M, Civitelli D, de Marco EV, Pasqua AA, et al. The dopamine D2 receptor gene is a susceptibility locus for Parkinson's disease. Mov Disord 2000; 15:127-131.
19. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997; 6:577-582.
20. Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P, Sedvall GC. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999; 4:290-296.
21. Cravchik A, Sibley DR, Gejman PV. Functional analysis of the human D2 dopamine receptor missense variants. J Biol Chem 1996; 271:26013-26017.
22. Yu AM, Idle JR, Gonzalez FJ. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev 2004; 36:243-277.
23. Ozdemir V, Bertilsson L, Miura J, Carpenter E, Reist C, Harper P, et al. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk re-visited. Pharmacogenet Genomics 2007; 17:339-347.
24. Suzuki Y, Sawamura K, Someya T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and Cytochrome P4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients. Neuropsychopharmacol 2006; 31:825-831.
25. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53:111-122.
26. Nakazono Y, Abe H, Murakami H, Koyabu N, Isaka Y, Nemoto Y, et al. Association between neuroleptic drug-induced extrapyramidal symptoms and dopamine D2-receptor polymorphisms in Japanese schizophrenic patients. Int J Clin Pharmacol Ther 2005; 43:163-171.
27. Kirchheiner J, Henckel HB, Franke L, Meineked I, Tzvetkovd M, Uebelhackc R, et al. Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet Genomics 2005; 15:579-587.
28. Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet 2003; 116:103-125.
29. Lewy H, Haus E, Ashkenazi IE. Possible linkage between the ability to change the period (tau) of the prolactin and cortisol rhythms in women and breast cancer risk. Chronobiol Int 2007; 24:365-381.
30. Harvey PW, Everett DJ, Springall CJ. Hyperprolactinemia as an adverse effect in regulatory and clinical toxicology: role in breast cancer and prostate cancer. Hum Exp Toxicol 2006; 25:395-404.